18.54

3.79% -0.73

After Hours: 18.54

Castle Biosciences Inc (CSTL)

Overview News Price History Option Chain Financials Why CSTL Down? Discussions Forecast

Castle Biosciences Inc stock is traded at $18.54, with a volume of 581.56K. It is down -3.79% in the last 24 hours and up +10.69% over the past month. Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

Previous Close:

$19.27

Open:

$19.12

24h Volume:

581.56K

Relative Volume:

1.34

Market Cap:

$520.86M

Revenue:

$219.79M

Net Income/Loss:

$-57.47M

P/E Ratio:

-8.6233

EPS:

-2.15

Net Cash Flow:

$-19.25M

1W Performance:

+2.77%

1M Performance:

+10.69%

6M Performance:

-34.12%

1Y Performance:

-18.76%

1-Day Range:

$18.08

$19.36

1-Week Range:

$17.96

$19.38

52-Week Range:

$15.45

$35.84

Castle Biosciences Inc Stock (CSTL) Company Profile

Name

Castle Biosciences Inc

Sector

Healthcare (1172)

Industry

Diagnostics & Research (54)

Phone

866-788-9007

Address

505 S FRIENDSWOOD DRIVE, FRIENDSWOOD, TX

Employee

784

Twitter

@castlebio

Next Earnings Date

2024-11-04

Latest SEC Filings

CSTL's Discussions on Twitter

Compare CSTL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CSTL Castle Biosciences Inc	18.54	520.86M	219.79M	-57.47M	-19.25M	-2.15
TMO Thermo Fisher Scientific Inc	390.26	156.49B	42.90B	6.52B	6.72B	17.05
DHR Danaher Corp	195.75	145.01B	23.82B	3.77B	4.90B	5.15
IDXX Idexx Laboratories Inc	520.59	42.30B	3.93B	894.97M	837.70M	10.82
A Agilent Technologies Inc	116.09	34.24B	6.63B	1.17B	1.19B	4.05
IQV Iqvia Holdings Inc	154.10	27.64B	15.50B	1.33B	2.16B	7.34

Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-14-23	Initiated	Guggenheim	Buy
Jan-05-23	Initiated	Scotiabank	Sector Outperform
Jan-07-22	Initiated	Stephens	Overweight
Apr-30-21	Initiated	Lake Street	Buy
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight
Dec-27-19	Reiterated	Canaccord Genuity	Buy
Aug-19-19	Initiated	BTIG Research	Buy
Aug-19-19	Initiated	Canaccord Genuity	Buy
Aug-19-19	Initiated	Robert W. Baird	Outperform
Aug-19-19	Initiated	SVB Leerink	Outperform

View All

Castle Biosciences Inc Stock (CSTL) Latest News

Jun 16, 2025

Castle Biosciences, SciBase Partner to Develop Predictive Tests for Skin Conditions - marketscreener.com

Jun 16, 2025

Castle Biosciences partners with SciBase for diagnostic tests (CSTL) - Seeking Alpha

Jun 16, 2025

Castle Biosciences enters collaboration, license agreement with Scibase to develop diagnostic tests for dermatologic diseases - marketscreener.com

Jun 16, 2025

Castle Biosciences Enters Collaboration and License Agreement wi - GuruFocus

Jun 16, 2025

Castle Biosciences (CSTL) Partners with SciBase for Dermatology Advancements | CSTL Stock News - GuruFocus

Jun 16, 2025

Castle Biosciences partners with SciBase to develop atopic dermatitis test - Investing.com

Jun 16, 2025

SciBase signs license agreement with Castle Biosciences to develop dermatology diagnostic tests - marketscreener.com

Jun 16, 2025

Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases - The Manila Times

Jun 16, 2025

SciBase resolves on a directed share issue of SEK 19 million and announces its intention to carry out an additional directed share issue of approximately SEK 11 million - TradingView

Jun 16, 2025

Castle Biosciences Enters Collaboration and License - GlobeNewswire

Jun 16, 2025

New Diagnostic Test Could Predict Atopic Dermatitis Flares Before Symptoms Appear - Stock Titan

Jun 16, 2025

Jun 15, 2025

Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Sold by Harbor Capital Advisors Inc. - Defense World

Jun 15, 2025

Jun 14, 2025

Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards® - Barchart.com

Jun 14, 2025

Jun 11, 2025

Castle Biosciences' Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention | CSTL Stock News - GuruFocus

Jun 11, 2025

Castle Biosciences’ Chief Executive Officer Derek Maetzold - GlobeNewswire

Jun 11, 2025

Castle Biosciences’ Chief Executive Officer Derek Maetzold to Participate in Panel Discussion ... - Bluefield Daily Telegraph

Jun 11, 2025

Castle Biosciences’ Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention - Barchart.com

Jun 11, 2025

Jun 08, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World

Jun 08, 2025

Jun 06, 2025

Two Sigma Advisers LP Acquires New Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World

Jun 06, 2025

Jun 05, 2025

Squarepoint Ops LLC Lowers Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World

Jun 05, 2025

Jun 04, 2025

Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards® - The Manila Times

Jun 04, 2025

Castle Biosciences’ Founder, President and CEO Derek - GlobeNewswire

Jun 04, 2025

Jun 01, 2025

ProShare Advisors LLC Makes New $230,000 Investment in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World

Jun 01, 2025

May 30, 2025